A Basket Trial of Vunakizumab in Inflammatory Skin Diseases
NCT06794671 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000
Last updated 2025-01-27
Summary
This is a national multi-center, large sample size case registration clinical study. The registry population was patients with inflammatory skin diseases who were receiving treatment with vunakizumab. All outpatient and inpatient patients with inflammatory skin diseases who were receiving vunakizumab were eligible for enrollment. Patients' usual care was not affected by participation in the study. We only collected data in routine clinical practice.
The study had an enrollment period of 5 years or 10,000 patients were recruited early, whichever occurred first. All patients must provide written informed consent form before data collection, and each patient will be followed for 1 year to observe clinical progression.
Conditions
- Inflammatory Skin Diseases
- Psoriasis
Sponsors & Collaborators
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-01
- Primary Completion
- 2031-12-31
- Completion
- 2031-12-31
More Related Trials
-
A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
NCT06663943 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
NCT00001761 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis
NCT05152563 ·Status: WITHDRAWN ·Phase: PHASE3
-
Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy
NCT03936894 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06411899 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
NCT07153666 ·Status: RECRUITING
-
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
NCT05522517 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360 ·Status: RECRUITING ·Phase: PHASE3
-
A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center
NCT06949241 ·Status: ACTIVE_NOT_RECRUITING
-
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
NCT05649098 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
NCT05524311 ·Status: COMPLETED ·Phase: PHASE2
-
JAK Inhibitors' Efficacy in Bullous Pemphigoid
NCT06561256 ·Status: COMPLETED
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
NCT06768671 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Anakinra for Inflammatory Pustular Skin Diseases
NCT01794117 ·Status: COMPLETED ·Phase: PHASE2
-
Adalimumab in JIA-associated Uveitis Stopping Trial
NCT03816397 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
NCT04206553 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
NCT05819398 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
NCT00472030 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
NCT07007637 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE3
-
Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial
NCT02298062 ·Status: COMPLETED ·Phase: PHASE3
-
The Role Of Neutrophil Proteases As Global Regulators Of Il-1 Family Cytokine Activity In Skin Disorders
NCT04750161 ·Status: UNKNOWN
-
Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis
NCT06201715 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy
NCT00329381 ·Status: COMPLETED ·Phase: PHASE4
-
Comparative Analysis of the Th17 Cellular Response in Active and Inactive Pemphigus Vulgaris Patients
NCT04096222 ·Status: UNKNOWN
-
First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects
NCT03103451 ·Status: COMPLETED ·Phase: PHASE1